OMERNGMHealthcare·Biotechnology#174 in industry

Omeros Corporation

Reports in 17d· 2026-05-14

+16.3% · 90d

$14.74

+1.21 (+8.94%)

After-Hours $14.89(+0.15)

News

(1)

March 2026

Mar 31, 20263 weeks ago8-KHealthcare

OMEROS CORP — 8-K Filing

OMEROMEROS CORP

# 🧾 What This Document Is This is an 8-K filing, which is like a company's "major news bulletin" for the stock market. Omeros is using it to report its financial results for the last quarter and full year of 2025, and more importantly, to announce some huge company-making news. You'll get the numbe

Read summaryView on SEC EDGAR

Key Data

Market Cap$1.06B

Open$13.50

Prev Close$13.53

Day Range$13.48 – $14.99

52W Range$2.95 – $17.65

Volume1,910,676

P/E (TTM)—

EPS$-0.08

Dividend Yield—

Beta2.53

Price Target$38.00(+157.8%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Buy4 analysts

Buy 2Hold 2Sell 0

About

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Healthcare · Biotechnology

175 employees

www.omeros.com